Position

Professor, Department of Pathology and Molecular Medicine
Canada Research Chair in Molecular Hemostasis
Career Investigator of the Heart and Stroke Foundation of Ontario

Education

St. Mary's Hospital Medical School, University of London, United Kingdom

Selected Administrative Appointments

World Health Organization/World Federation of Hemophilia Working Group on Genetic Diagnosis in the Hemophilias, 1991-1992
International Society for Thrombosis and Haemostasis Scientific Standardisation Committee on VWD, 1998-Present
Member, Medical and Scientific Advisory Council (MASAC) for the National Hemophilia Foundation (USA), 2002-Present
Member, Gene Therapy Working Group of the National Hemophilia Foundation (USA), 2000-Present
International Society for Thrombosis and Haemostasis Council of the Scientific Standardisation Committee, 2002-Present

Research Interests

All of the research being undertaken by this group relates to molecular aspects of the hemostatic (coagulation) system. In the normal physiological state, a delicate balance is preserved between pro- and anti-coagulant factors that contributes to the maintenance of the normal circulation. When this balance is disrupted, bleeding or thrombosis occurs.

This research program utilizes the potential of molecular genetics and molecular biology to address a variety questions relating to pathological hemostasis. The studies range from an investigation of the mechanisms regulating production of the adhesive hemostatic protein, von Willebrand Factor, to the development of strategies for gene therapy for the inherited bleeding disease, hemophilia.

Publications

2009

James, P., Lillicrap, D.
The role of molecular genetics in diagnosing von Willebrand disease.
Semin. Thromb. Hemost. 34(6):502-8, 2009

Lillicrap, D.
The improved factor concentrate
Haemostaseologie 28(1):71-3, 2009

Waters B, Qadura M, Burnett E, Chegeni R, Labelle A, Thompson P, Hough C, Lillicrap D.
Anti-CD3 therapy in hemophilia A mice prevents factor VIII inhibitor formation by increasing regulatory CD4⁺CD25⁺ T cells.
Blood, 113:193-203, 2009

Vincent AM, Lillicrap D, Boulanger A, Meilleur C, Amesse C, St-Louis J, Rivard GE.
Non-neutralizing anti-FVIII antibodies: different binding specificity to different recombinant FVIII concentrates.
Haemophilia. 2009 Jan;15(1):374-6

Qadura M, Waters B, Burnett E, Chegeni R, Bradshaw S, Hough C, Othman M, Lillicrap
Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice.D.
Blood. 2009 May 1. [Epub ahead of print]

Matsui H, Shibata M, Brown B, Labelle A, Hegadorn C, Andrews C, Chuah M, Vandendriessche T, Miao CH, Hough C, Lillicrap D.
A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3+ T regulatory cells.
Blood. 2009 May 20. [Epub ahead of print]

2008

Stakiw J, Bowman M, Hegadorn C, Pruss C, Notley C, Groot E, Lenting P, Lillicrap D, James PD.
The Effect of Exercise on Individuals with Type 1 and Type 2B von Willebrand Disease (VWD).
J.Thromb.Haemostas. 6:90-96, 2008

Prasad S, Lillicrap D, Labelle A, Knappe S, Keller T, Burnett E, Powell S, Johnson KW.
Efficacy and Safety of a New-Class of Hemostatic Drug Candidate, AV513, in Hemophilia A Dogs
Blood, 111:272-279, 2008

Rubinger M, Lillicrap D, Rivard GE, Teitel J, Carcao M, Hensman C, Walker I. The association of Hemophilia Clinic Directors of Canada.
A prospective surveillance study of factor VIII inhibitor development in the Canadian hemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose.
Haemophilia 14:281-6, 2008

Hough C, Cameron C, Notley C, Brown C, O’Brien L, Keightley A,M, Berber E, Lillicrap D.
Influence of a GT Repeat Element on Shear Stress-Responsiveness of the VWF Gene Promoter.
J.Thromb.Haemost. 6 (7):1183-70, 2008

Pruss,C.M., Notley, C.R.P., Hegadorn, C.A., O'Brien, L.A., Lillicrap, D.
ADAMTS13 Cleavage Efficiency is Altered by Polymorphic and Mutagenic Sequence Changes in the A1 and A2 Domains of von Willebrand Factor (VWF).
Br.J.Haematol 143:552-558, 2008. 

James PD, Stakiw J, Leggo J, Walker I, Lillicrap D.
A case of non-resolving hemophilia B Leyden in a 42-year-old male (F9 promoter + 13 A>G)
J Thromb Haemost. 6(5):885-6, 2008

Robertson J, Lillicrap D, James PD.
von Willebrand disease.
Pediatr Clin North Am. 55(2):377-92, 2008

Pipe SW, High KA, Ohashi K, Ural AU, Lillicrap D.
Progress in the molecular biology of inherited bleeding disorders.
Haemophilia. 14 Suppl 3:130-7, 2008

Collins PW, Cumming AM, Goodeve AC, Lillicrap D.
Type 1 von Willebrand disease: application of emerging data to clinical practice.
Haemophilia. 14(4):685-96, 2008

Qadura M, Othman M, Waters B, Chegeni R, Walker K, Labelle A, Hough C, Lillicrap D.
Reduction of the immune response to Factor VIII mediated through tolerogenic Factor VIII presentation by immature dendritic cells.
J.Thromb.Haemostas. 6:2095-104, September 2008

Bowman M, Mundell G, Grabell J, Hopman WM, Rapson D, Lillicrap D, James P.
Generation and validation of the Condensed MCMDM-1VWD Bleeding Questionnaire for von Willebrand disease.
J Thromb Haemost.6:2062-6, 2008

2007

James PD, Notley C, Hegadorn C, Leggo J, Tuttle A, Tinlin S, Brown C, Andrews C, Labelle A, Chirinian Y, O’Brien L, Othman M, Rivard G, Rapson D, Hough C, Lillicrap D
The Mutational Spectrum of Type 1 von Willebrand Disease: Results from a Canadian Cohort Study.
Blood 109:145-54, 2007

Othman M, Labelle A, Mazzetti I, Elbatarny H and Lillicrap D
Adenovirus-induced thrombocytopenia: The role of P-selectin and von Willebrand factor in mediating accelerated platelet clearance.
Blood 109:2832-39, 2007

Matsui H, Shibata M, Brown B, Labelle A, Hegadorn C, Andrews C, Hebbel RP, Galipeau J, Hough C, Lillicrap D
Ex vivo gene therapy for Hemophilia A that enhances safe delivery and sustained in vivo FVIII expression from lentivirally-engineered endothelial progenitors.
Stem Cells, 25:2660-2669, 2007

Barnes C, Blanchette V, Lillicrap D, Mann K, Stain AM, Leggo J, Carcao M.
Different clinical phenotype in triplets with Haemophilia A
Haemophilia 13:202-5, 2007

Lenting PJ, de Groot PG, Denis CV, Marx I, Lillicrap D, Pruss C, Vanhoorelbeke K, De Meyer SF
Correction of the bleeding time in von Willebrand factor (VWF)-deficient mice using murine VWF.
Blood, 109: 2267-2268, 2007

James PD, Notley C, Hegadorn C, Poon MC, Walker I, Rapson D, Association of Hemophilia Clinic Directors of Canada, Lillicrap D.
Challenges in Defining Type 2M von Willebrand Disease: Results from a Canadian Cohort Study.
J.Thromb.Haemostas. 5:1914-1922, 2007

Lillicrap D.
Von Willebrand disease - phenotype versus genotype: deficiency versus disease.
Thromb Res. 120 Suppl 1:S11-6, 2007

Othman M, Lillicrap D.
Distinguishing between non-identical twins: platelet type and type 2B von Willebrand disease.
Br J Haematol. 138(5):665-6, 2007.

Pierce GF, Lillicrap D, Pipe SW, Vandendriessche T.
Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment.
J Thromb Haemost. 5(5):901-6, 2007.

Lillicrap D.
Inducing Tregs with hepatic gene therapy .
Blood 110: 1089, 2007

2006

van Damme A, Thorrez L, Ma L, Vandenburgh H, Eyckmans J, Dell’accio F, De Bari C, Luyten F, Lillicrap D, Coleen D
Efficient lentiviral transduction and improved engraftment of human bone marrow mesenchymal cells
Stem Cells 24:896-907, 2006.

Roland K, Rapson D, Lillicrap D, James P
The value of genetic testing for Type 2B von Willebrand Disease.
Clin.Lab Haem 28:17-21, 2006

James PD, Paterson AD, Notley C, Hegadorn C, Tinlin C, Brown C, Tuttle A, Association of Hemophilia Clinic Directors of Canada, Lillicrap D
Genetic linkage and association analysis in Type 1 von Willebrand Disease (VWD): Results from the Canadian Type 1 VWD Study.
J.Thromb.Hemost. 4:783-92, 2006.

Lillicrap D, Nair SC, Srivastava A, Rodeghiero F, Pabinger I, Federici AB
Laboratory issues in bleeding disorders.
Haemophilia 12 Suppl 3:68-75, 2006

Lillicrap D, Vandendriessche T, High K
Cellular and genetic therapies for haemophilia.
Haemophilia. 12 Suppl 3:36-41, 2006

Dimichele D, Chuansumrit A, London AJ, Thompson AR, Cooper CG, Killian R
Ross, LF, Lillicrap D, Kimmelman J
Ethical issues in haemophilia.
Haemophilia. 12 Suppl 3:30-5, 2006

Jiang H, Lillicrap D, Patarroyo-White S, Liu T, Qian X, Scallan CD, Powell S, Keller T, McMurray M, Labelle A, Nagy D, Vargas JA, Zhou S, Couto LB, Pierce GF
Multi-year Therapeutic Benefit of AAV Serotypes 2, 6 and 8 Delivering Factor VIII to Hemophilia A Mice and Dogs.
Blood 108:107-15, 2006.

James P and Lillicrap D
Genetic Testing for von Willebrand Disease: The Canadian Experience
Seminars in Thrombosis and Haemostasis, 32:546-52, 2006

Berber E, Leggo J, Brown C, Berber E, Gallo N, Feilotter, H, Lillicrap D
DNA Microarray Analysis for the Detection of Mutations in Hemophilia A.
Journal of Thrombosis and Haemostasis, 4:1756-62, 2006

Rawle FE, Pratt KP, Labelle A, Weiner HL, Hough C, Lillicrap D
Induction of Partial Immune Tolerance to Factor VIII Through Prior Mucosal Exposure to the Factor VIII C2 Domain.
Journal of Thrombosis and Haemostasis, 4:2172-9, 2006

Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nicols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, Federici AB, The Working Party on von Willebrand Disease classification.
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.
J Thromb Haemost 4:2103-14, 2006

Lee CA, Lillicrap D, Astermark J
Inhibitor development in hemophiliacs; the roles of genetic versus environmental factors.
Semin Thromb Hemost 32 Suppl 2:10-4, 2006

Feldman BM, Pai M, Rivard GE, Israels S, Poon M-C, Demers C, Robinson S, Luke KH, Wu J, Gill K, Lillicrap D, Babyn P, McLimont M, Blanchette VS. Association of Hemophilia Clinic Directors of Canada Prophylaxis Study Group
Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study (CHPS).
J Thromb Hemost 4:1228-36, 2006.

Barnes C, Lillicrap D, Pazmino-Canizares J, Blanchette, VS, Stain, AM, Clark, D, Hensmen, C, Carcao, M
Pharmacokinetics of recombinant Factor VIII (Kogenate-FS) in children and causes of inter patient pharmacokinetic variability. Haemophilia, 12 Suppl 4:40-9, 2006

Lillicrap D.
The Role of Immunomodulation in the Management of Factor VIII Inhibitors
Hematology Am Soc Hematol Educ Program 421-5, 2006